iBio (IBIO) Stock Forecast & Price Target

iBio is favorably positioned because IBIO-610 has shown unusually deep and durable Activin E blockade in obese NHPs, with up to 98% suppression at week 4 and 97% at week 8, plus a 33.2-day NHP half-life and projected human half-life near 100 days, supporting infrequent dosing. The thesis is further strengthened by consistent rodent and NHP body-composition effects, including lower visceral and total fat, slight lean-mass gains, and improved semaglutide combination activity with reduced lean-mass loss, which aligns with genetically validated Activin E biology. Beyond IBIO-610, the broader platform adds value through IBIO-600 and IBIO-800, while the company’s internal consistency across four molecules and clean preclinical profile suggest a differentiated precision-antibody platform with meaningful upside potential.

iBio is a development-stage biotechnology company with no revenue-generating products, persistent operating losses, and a clear need for future debt or equity financing to fund research, trials, and commercialization infrastructure, which heightens dilution and liquidity risk. Its pipeline remains highly speculative because IBIO-600 and IBIO-610 are still unproven in humans, while clinical, regulatory, and competitive risks could delay approval or undermine efficacy and safety, and the company’s dependence on a few early assets makes execution risk especially concentrated. Despite mechanistic rationale and some preclinical promise, the investment case remains fragile because even favorable readouts must overcome a 12.0% WACC, -5.0% terminal growth framework, and the reality that large, better-funded competitors may outpace iBio before it can validate its platform.